Intravenous Immunoglobulin (IVIG) from CSL Behring.
Privigen is a 10% liquid IVIG product manufactured by CSL Behring. It is approved for primary humoral immunodeficiency as well as for chronic ITP and CIDP. It is one of the most widely used IVIG products in the United States.
Privigen is FDA-approved for the following indications:
Privigen is administered intravenously, typically every three to four weeks. Like other IVIG products, infusion can be performed at home, on-site at Horizon Infusions, or at a partner infusion center.
The manufacturer offers a patient support program — CSL Behring IgIQ Patient Support — that can help with insurance navigation, copay assistance for eligible patients, nursing support, and ongoing education. More information is available at https://www.igiq.com.
Treatment with Privigen is initiated and monitored by Dr. McNeil. Prior authorizations are handled in-house — patients are not asked to navigate insurance approvals on their own. Infusion logistics are coordinated through trusted partner infusion providers — including Horizon Infusions, where the practice is co-located — or arranged for home infusion when appropriate. The team handles scheduling, nursing coordination, and prior-authorization renewals.
Important safety note: This page is not a substitute for the FDA prescribing information. Risks, contraindications, drug interactions, and required monitoring vary by patient. The official manufacturer website (https://www.privigen.com) provides the most current full prescribing and safety information. Treatment decisions and monitoring are individualized — please discuss with Dr. McNeil whether Privigen is appropriate for your situation.
Donald L. McNeil, MD · Board Certified in Allergy & Immunology and Internal Medicine
This page is provided for educational purposes only and is not medical advice. If you have an emergency, call 911.